Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-small Cell Lung Cancer, A Collaborative Project Orbis Review.
Vellanki PJ, Mulkey F, Jaigirdar AA, Rodriguez L, Wang Y, Xu Y, Zhao H, Liu J, Howe G, Wang J, Choo Q, Golding SJ, Mansell V, Korsah K, Spillman D, de Claro RA, Pazdur R, Beaver JA, Singh H. Vellanki PJ, et al. Clin Cancer Res. 2021 Jul 1;27(13):3522-3527. doi: 10.1158/1078-0432.CCR-20-4338. Epub 2021 Feb 25. Clin Cancer Res. 2021. PMID: 33632925 Free PMC article. Clinical Trial.
FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review.
Koch AL, Vellanki PJ, Drezner N, Li X, Mishra-Kalyani PS, Shen YL, Xia H, Li Y, Liu J, Zirkelbach JF, Palazov E, Gamarian A, Choo Q, Girčys A, Rohr UP, Fesenko N, Spillman D, Pazdur R, Beaver JA, Singh H. Koch AL, et al. Among authors: vellanki pj. Clin Cancer Res. 2021 Dec 15;27(24):6638-6643. doi: 10.1158/1078-0432.CCR-21-1034. Epub 2021 Jul 22. Clin Cancer Res. 2021. PMID: 34301748 Clinical Trial.
FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.
Nakajima EC, Vellanki PJ, Larkins E, Chatterjee S, Mishra-Kalyani PS, Bi Y, Qosa H, Liu J, Zhao H, Biable M, Hotaki LT, Shen YL, Pazdur R, Beaver JA, Singh H, Donoghue M. Nakajima EC, et al. Among authors: vellanki pj. Clin Cancer Res. 2022 Feb 1;28(3):446-451. doi: 10.1158/1078-0432.CCR-21-1466. Epub 2021 Aug 30. Clin Cancer Res. 2022. PMID: 34462287 Free PMC article.
Regulatory implications of ctDNA in immuno-oncology for solid tumors.
Vellanki PJ, Ghosh S, Pathak A, Fusco MJ, Bloomquist EW, Tang S, Singh H, Philip R, Pazdur R, Beaver JA. Vellanki PJ, et al. J Immunother Cancer. 2023 Feb;11(2):e005344. doi: 10.1136/jitc-2022-005344. J Immunother Cancer. 2023. PMID: 36796877 Free PMC article. Review.
Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes.
Balaji A, Zhang J, Wills B, Marrone KA, Elmariah H, Yarchoan M, Zimmerman JW, Hajjir K, Venkatraman D, Armstrong DK, Laheru DA, Mehra R, Ho WJ, Reuss JE, Heng J, Vellanki P, Donehower RC, Holdhoff M, Naidoo J. Balaji A, et al. J Oncol Pract. 2019 Sep;15(9):e825-e834. doi: 10.1200/JOP.18.00703. Epub 2019 Aug 6. J Oncol Pract. 2019. PMID: 31386608 Free PMC article.
The Retrofit: Lessons From Sotorasib's Dosing Conundrum.
Singh H, Vellanki PJ, Pazdur R. Singh H, et al. Among authors: vellanki pj. J Clin Oncol. 2024 Oct 7:JCO2400310. doi: 10.1200/JCO.24.00310. Online ahead of print. J Clin Oncol. 2024. PMID: 39374478 No abstract available.
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group.
Wyatt AW, Litiere S, Bidard FC, Cabel L, Dyrskjøt L, Karlovich CA, Pantel K, Petrie J, Philip R, Andrews HS, Vellanki PJ, Tolmeijer SH, Villalobos Alberu X, Alfano C, Bogaerts J, Calvo E, Chen AP, Toledo RA, de Vries EGE, Seymour L, Laurie SA, Garralda E; RECIST ctDNA workshop group. Wyatt AW, et al. Among authors: vellanki pj. Clin Cancer Res. 2024 Nov 15;30(22):5034-5041. doi: 10.1158/1078-0432.CCR-24-1883. Clin Cancer Res. 2024. PMID: 39269996 Review.
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations.
Mehta GU, Vellanki PJ, Ren Y, Amatya AK, Mishra-Kalyani PS, Pan L, Zirkelbach JF, Pan Y, Liu J, Aungst SL, Miller CP, Shah M, Rahman NA, Theoret M, Kluetz P, Pazdur R, Beaver JA, Singh H. Mehta GU, et al. Among authors: vellanki pj. Oncologist. 2024 Aug 5;29(8):667-671. doi: 10.1093/oncolo/oyae151. Oncologist. 2024. PMID: 38970465 Free PMC article. Clinical Trial.
11 results